Maltodextrin ( DrugBank: Maltodextrin )

4 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2
13	Multiple sclerosis/Neuromyelitis optica	1
96	Crohn disease	3
97	Ulcerative colitis	3

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04829760 (ClinicalTrials.gov)	May 13, 2021	31/3/2021	The Effect of Psyllium and Wheat Bran on Body Weight in People With Parkinson's Disease and Constipation Symptoms	The Effect of Psyllium and Wheat Bran on Body Weight in People With Parkinson's Disease and Constipation Symptoms	Parkinson Disease	Dietary Supplement: Psyllium;Dietary Supplement: Coarse wheat bran;Dietary Supplement: Maltodextrin	University of Florida	NULL	Recruiting	40 Years	85 Years	All	79	N/A	United States
2	NCT03667404 (ClinicalTrials.gov)	November 6, 2018	10/9/2018	Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study	Gut Microbial Remodeling With Resistant Maltodextrin for Motor and Non-motor Symptoms in Parkinson's Disease: Safety and Tolerability Study	Parkinson Disease;Intestinal Bacteria Flora Disturbance;Dietary Modification	Dietary Supplement: maltodextrin;Dietary Supplement: Resistant maltodextrin	Northwestern University	University of Illinois at Chicago	Active, not recruiting	60 Years	N/A	All	30	Phase 2	United States

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01879202 (ClinicalTrials.gov)	December 2012	7/11/2012	Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis	Methylphenidate Modified-release as Treatment of MS-associated Fatigue. A Single-center Randomized Double-blind Placebo-controlled Study.	Multiple Sclerosis;Fatigue	Drug: Methylphenidate modified release;Drug: Maltodextrin	Medical University of Vienna	NULL	Recruiting	18 Years	N/A	Both	96	Phase 2	Austria

96. Crohn disease

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04804046 (ClinicalTrials.gov)	July 15, 2021	11/3/2021	Synbiotics and Post-op Crohn's Disease	Defining Microbial and Immune Changes Following Synbiotic Supplementation in Post-operative Crohn's Disease Patients	Crohn's Disease	Dietary Supplement: Synbiotic;Other: Digestible Maltodextrin	University of Alberta	W. Garfield Weston Foundation	Recruiting	18 Years	75 Years	All	36	N/A	Canada
2	NCT03950336 (ClinicalTrials.gov)	February 4, 2020	13/5/2019	Prebiotics and Diet to Reduce Leaky Gut in First Degree Relatives of Crohn's Disease Patients	Influence of Prebiotics on Intestinal Permeability in First Degree Relatives of Crohn's Patients	Healthy First Degree Relatives of Crohn's Disease Patients	Dietary Supplement: Prebiotics;Other: Low n-6 PUFA Diet;Dietary Supplement: Maltodextrin;Other: Control Diet	University of Alberta	NULL	Recruiting	15 Years	50 Years	All	40	N/A	Canada
3	NCT01487759 (ClinicalTrials.gov)	March 2008	6/12/2011	Prebiotic Effect on Metabolites in Crohn's Disease	Metabolite Profiling of the Impact of Oligofructose Enriched Inulin in Crohn's Disease Patients	Crohn Disease	Dietary Supplement: Oligofructose enriched inulin;Dietary Supplement: Maltodextrin	Katholieke Universiteit Leuven	NULL	Completed	18 Years	N/A	Both	67	N/A	Belgium

97. Ulcerative colitis

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000032498	2020-09-01	2020-04-30	Human experimental study on the effect of probiotics combined with prebiotics on ulcerative colitis: a randomized double-blind controlled trial	Human experimental study on the effect of probiotics combined with prebiotics on ulcerative colitis	Ulcerative colitis	Experimental group:Probiotics and prebiotics;placebo group:maltodextrin;	Capital Medical University	NULL	Pending			Both	Experimental group:15;placebo group:15;		China
2	ChiCTR2000033953	2020-07-01	2020-06-18	Effect of the probiotic on symptoms in patients with ulcerative colitis (UC)	Effect of the probiotic on symptoms in patients with ulcerative colitis (UC)	Ulcerative colitis	Placebo group:Maltodextrin;experimental group 1:Lactobacillus plantarum CCFM8610;experimental group 2:Lactobacillus plantarum N13;experimental group 3:Lactobacillus casei CCFM1059;	Jiangnan University	NULL	Pending			Both	Placebo group:20;experimental group 1:20;experimental group 2:20;experimental group 3:20;		China
3	NCT02865707 (ClinicalTrials.gov)	August 2016	12/7/2016	Ulcerative Colitis Relapse Prevention by Prebiotics	Prevention of Ulcerative Colitis by Prebiotics: Efficacy and Protective Mechanisms	Ulcerative Colitis	Dietary Supplement: Synergy-1;Dietary Supplement: Maltodextrin	University of Alberta	University of British Columbia	Completed	18 Years	75 Years	All	89	N/A	Canada